HLS Therapeutics (HLS) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HLS shares.
View HLS analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1 year price objectives for HLS Therapeutics' stock. Their HLS share price forecasts range from C$15.00 to C$26.50. On average, they anticipate the company's share price to reach C$19.80 in the next year. This suggests a possible upside of 360.5% from the stock's current price.
View analysts price targets for HLS or view top-rated stocks among Wall Street analysts.

HLS Therapeutics' stock was trading at C$9.83 at the beginning of the year. Since then, HLS shares have decreased by 56.3% and is now trading at C$4.30.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our HLS earnings forecast.

HLS Therapeutics Inc. (TSE:HLS) announced its quarterly earnings data on Thursday, March, 16th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.18. The business had revenue of $21.28 million for the quarter, compared to analyst estimates of $22.56 million. HLS Therapeutics had a negative net margin of 41.79% and a negative trailing twelve-month return on equity of 18.55%.

HLS Therapeutics announced a quarterly dividend on Thursday, April 27th. Stockholders of record on Thursday, June 15th will be paid a dividend of 0.05 per share on Thursday, June 15th. This represents a $0.20 annualized dividend and a dividend yield of 4.65%. The ex-dividend date is Thursday, April 27th.
Read our dividend analysis for HLS.

HLS Therapeutics (TSE:HLS) pays an annual dividend of C$0.20 per share and currently has a dividend yield of 4.61%. HLS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for HLS.

Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Cargojet (CJT), Fairfax Financial (FFH), Fortis (FTS), Aurora Cannabis (ACB), Aphria (APHA), Alimentation Couche-Tard (ATD.B), BlackBerry (BB), BCE (BCE), Bank of Montreal (BMO) and Bank of Nova Scotia (BNS).

HLS Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HLS."

Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

One share of HLS stock can currently be purchased for approximately C$4.30.

HLS Therapeutics (TSE:HLS) has a market capitalization of C$139.11 million and generates C$61.67 million in revenue each year. The company earns C$-25,770,000.00 in net income (profit) each year or C($1.12) on an earnings per share basis.

The official website for the company is www.hlstherapeutics.com. The company can be reached via phone at 647-495-9000.